CA2383224A1 - Extracts of orange peel for prevention and treatment of cancer - Google Patents
Extracts of orange peel for prevention and treatment of cancer Download PDFInfo
- Publication number
- CA2383224A1 CA2383224A1 CA002383224A CA2383224A CA2383224A1 CA 2383224 A1 CA2383224 A1 CA 2383224A1 CA 002383224 A CA002383224 A CA 002383224A CA 2383224 A CA2383224 A CA 2383224A CA 2383224 A1 CA2383224 A1 CA 2383224A1
- Authority
- CA
- Canada
- Prior art keywords
- extract
- methoxyflavone
- hydroxy
- animal
- resveratrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract 17
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 3
- 201000011510 cancer Diseases 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 230000004565 tumor cell growth Effects 0.000 claims abstract 3
- OMICQBVLCVRFGN-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1-benzopyran-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=CC=CC=C2O1 OMICQBVLCVRFGN-UHFFFAOYSA-N 0.000 claims 9
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 7
- 240000001341 Reynoutria japonica Species 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims 3
- 244000269722 Thea sinensis Species 0.000 claims 3
- 235000006468 Thea sinensis Nutrition 0.000 claims 3
- 235000020279 black tea Nutrition 0.000 claims 3
- 229940016667 resveratrol Drugs 0.000 claims 3
- 235000021283 resveratrol Nutrition 0.000 claims 3
- 229940092258 rosemary extract Drugs 0.000 claims 3
- 235000020748 rosemary extract Nutrition 0.000 claims 3
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims 3
- DOFJNFPSMUCECH-UHFFFAOYSA-N Demethylnobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 DOFJNFPSMUCECH-UHFFFAOYSA-N 0.000 claims 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims 2
- UYCWETIUOAGWIL-UHFFFAOYSA-N Isosinensetin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OC)C(OC)=C2O1 UYCWETIUOAGWIL-UHFFFAOYSA-N 0.000 claims 1
- HIUKQMVQSJHRNC-UHFFFAOYSA-N Isosinensetin Natural products C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(OC)=C2O1 HIUKQMVQSJHRNC-UHFFFAOYSA-N 0.000 claims 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims 1
- 235000017807 phytochemicals Nutrition 0.000 abstract 1
- 229930000223 plant secondary metabolite Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compositions and methods of inhibiting tumor cell growth and treating and preventing cancer are provided based on administration of an orange peel extract either alone or in combination with other phytochemicals.
Claims (8)
1. An extract of orange peel comprising 4',5,6,7,8-pentamethoxyflavone and 3',4',5,6,7,8-hexamethoxyflavone.
2. The extract of claim 1 further comprising at least one compound selected from the group consisting of 5-hydroxy-6,7,8,3',4'-pentamethoxyflavone, 5-hydroxy-7,8,3',4'-methoxyflavone, 5,7-hydroxy-6,8,3',4'-methoxyflavone, 5,7,8,3',4'-pentamethoxyflavone, 5,7,8,4'-methoxyflavone,
3,5,6,7,8,3',4'-methoxyflavone, 5-hydroxy-3,6,7,8,3',4'-methoxyflavone, 5-hydroxy-6,7,8,4'-methoxyflavone, 5,6,7,4'-methoxyflavone, 7-hydroxy-3,5,6,8,3',4'-methoxyflavone, and 7-hydroxy-3,5,6,3',4'-methoxyflavone.
3. A composition comprising the extract of claim 1 and at least one other compound selected from the group consisting of rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a black tea extract, and a hydroxylated or methoxylated resveratrol analog.
3. A composition comprising the extract of claim 1 and at least one other compound selected from the group consisting of rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a black tea extract, and a hydroxylated or methoxylated resveratrol analog.
4. A composition comprising the extract of claim 2 and at least one other compound selected from the group consisting of rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a black tea extract, and a hydroxylated or methoxylated resveratrol analog.
5. A method for inhibiting tumor cell growth in an animal comprising administering to an animal the extract of claim 1 or claim 2.
6. A method for inhibiting tumor cell growth in an animal comprising administering to an animal the composition of claim 3 or claim 4.
7. A method for preventing or treating cancer in an animal comprising administering to an animal an effective amount of an extract of claim 1 or claim 2.
8. The method of claim 7 further comprising administering at least one additional compound selected from the group consisting of a rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a hydroxylated resveratrol analog, a black tea extract, and a methoxylated resveratrol analog.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15501899P | 1999-09-21 | 1999-09-21 | |
| US60/155,018 | 1999-09-21 | ||
| PCT/US2000/025733 WO2001021137A1 (en) | 1999-09-21 | 2000-09-20 | Extracts of orange peel for prevention and treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2383224A1 true CA2383224A1 (en) | 2001-03-29 |
| CA2383224C CA2383224C (en) | 2010-12-07 |
Family
ID=22553801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2383224A Expired - Fee Related CA2383224C (en) | 1999-09-21 | 2000-09-20 | Extracts of orange peel for prevention and treatment of cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1214040A4 (en) |
| JP (1) | JP2003509447A (en) |
| AU (1) | AU7384900A (en) |
| CA (1) | CA2383224C (en) |
| WO (1) | WO2001021137A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778128B2 (en) * | 2000-04-19 | 2004-11-18 | Nof Corporation | Cosmetic composition |
| EP1349560B1 (en) * | 2000-11-15 | 2012-07-11 | Rutgers, The State University of New Jersey | Black tea extract for prevention of disease |
| US7087790B2 (en) | 2003-08-29 | 2006-08-08 | Rutgers, The State University Of New Jersey | Benzotropolone derivatives and modulation of inflammatory response |
| US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| US20070042972A1 (en) * | 2005-05-24 | 2007-02-22 | Mckeever Kenneth H | Compositions and methods for optimizing exercise recovery |
| WO2007135569A2 (en) * | 2006-02-09 | 2007-11-29 | Kgk Synergize Inc | Methods of treating canine osteosarcoma |
| WO2008035208A2 (en) * | 2006-05-19 | 2008-03-27 | Kgk Synergize Inc | The use of flavonoids for the inhibition of cellular growth |
| CN100422168C (en) * | 2006-06-15 | 2008-10-01 | 中国科学技术大学 | Hesperetin derivant and preparation process thereof |
| DE102007037772A1 (en) * | 2007-08-10 | 2009-02-12 | Csabai, Zsolt, Dr. Ph. | Antioxidant complex based on Grape Vital (citrus and / or grape seed and / or flavonoid base) |
| JP5742050B2 (en) * | 2011-03-01 | 2015-07-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | NK cell activator and NK cell activation method |
| KR101337059B1 (en) | 2012-05-16 | 2013-12-06 | 연세대학교 산학협력단 | Composition for prevention or treatment of obesity comprising flavone compounds |
| US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
| SG10202006032VA (en) * | 2015-12-07 | 2020-07-29 | Univ Kyoto | Combination therapy based on pd-1 signal inhibitors |
| CN115772145A (en) * | 2022-11-29 | 2023-03-10 | 三峡大学 | Citrus fruit extract and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0824320A4 (en) * | 1995-05-05 | 2000-06-07 | Hauser Inc | High purity carnosic acid from rosemary and sage extracts by ph-controlled precipitation |
| JPH09176009A (en) * | 1995-12-27 | 1997-07-08 | Inahata Koryo Kk | New antimutagenic agent and substance having antimutagenic action |
| US5830738A (en) * | 1996-06-04 | 1998-11-03 | Clemson University | Extraction of pigment from plant material |
| US6251400B1 (en) * | 1997-09-26 | 2001-06-26 | Kgk Synergize Inc | Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols |
| JP3571899B2 (en) * | 1997-12-18 | 2004-09-29 | 小川香料株式会社 | Flavor deterioration inhibitor |
-
2000
- 2000-09-20 CA CA2383224A patent/CA2383224C/en not_active Expired - Fee Related
- 2000-09-20 WO PCT/US2000/025733 patent/WO2001021137A1/en active Application Filing
- 2000-09-20 AU AU73849/00A patent/AU7384900A/en not_active Abandoned
- 2000-09-20 EP EP00961973A patent/EP1214040A4/en not_active Withdrawn
- 2000-09-20 JP JP2001524564A patent/JP2003509447A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003509447A (en) | 2003-03-11 |
| CA2383224C (en) | 2010-12-07 |
| AU7384900A (en) | 2001-04-24 |
| WO2001021137A1 (en) | 2001-03-29 |
| EP1214040A1 (en) | 2002-06-19 |
| WO2001021137A8 (en) | 2001-07-26 |
| EP1214040A4 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2383224A1 (en) | Extracts of orange peel for prevention and treatment of cancer | |
| CA2431196A1 (en) | Black tea extract for prevention of disease | |
| WO2001080843A3 (en) | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| BG66087B1 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
| PL351280A1 (en) | Methods and compositions for treating solid tumors | |
| YU75003A (en) | A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer | |
| WO2001078701A3 (en) | Method and compositions for preventing hormone induced adverse effects | |
| CA2326761A1 (en) | Antitumor agent | |
| GEP20043375B (en) | APRIL-Receptor (BCMA) and Use Thereof | |
| GEP20043322B (en) | C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors | |
| CA2418479A1 (en) | Prodrugs of betulinic acid derivatives for the treatment of cancer | |
| WO2007147128A3 (en) | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone | |
| NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
| GEP20033079B (en) | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency | |
| KR100352030B1 (en) | Gum composition for removing nicotine | |
| AU4830097A (en) | Use of an extract of Cimicifuga | |
| MX9800945A (en) | Use of griseofulvin for inhibiting the growth of cancers. | |
| EP0819433A3 (en) | Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin | |
| IL117874A0 (en) | Pharmaceutical compositions for inhibiting the growth of viruses and cancers | |
| MXPA05003634A (en) | Extract with anti-tumor and anti-poisonous activity. | |
| MY134690A (en) | Antitumor therapy comprising distamycin derivatives. | |
| WO2002062952A3 (en) | Non-cytotoxic pap mutants | |
| NZ523606A (en) | Pharmaceutical compositions and methods for use | |
| PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140922 |